YGEN.L Regulatory News (YGEN)

Premaitha Health plc

("Premaitha" or the "Company")

Premaitha wins 'Outstanding NIPS Solution Provider of the Year' award

Manchester, UK - 13 June 2018: Premaitha Health plc (AIM:NIPT), a leading international molecular diagnostics group, is proud to announce that it has today been presented with the "Outstanding Non-invasive Prenatal Screening (NIPS) Solution Provider of the Year" award at the China & America Precision Medicine Forum in Shanghai.

The award recognises Premaitha's excellence as a leading provider of NIPS, through both the CE-IVD approved IONA® test, the Company's first product, and the more recently introduced Sage™ solution, Premaitha's advanced non-invasive prenatal testing ("NIPT") analysis tool.

Members of the Company's commercial team will be in attendance at the event to host an exhibition stand across the two days. In addition, Dr Robert C.Henke, Premaitha's Regional Director of Asia Pacific, will be presenting at the forum on "The Impact of CE-IVD Standardization and the Clinical Implications of NGS-Based Prenatal Screening."

The China & America Precision Medicine Forum aims to build a platform for international academic communication and industrial cooperation to discuss key areas across precision medicine including policies and regulations, international cooperation, sequencing technology and cell therapy.

Dr Stephen Little, CEO of Premaitha Health, commented: "We are delighted to be recognised as a leading provider of NIPS in a region that is becoming increasingly important to our business. We believe this award is not only testament to the quality of our market leading solutions, but also to our ability in raising awareness of these products in our key territories."

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests.

The Group's current primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market - although the Group intends to expand its product range into other areas of clinical genetics.

Premaitha's first product, the IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening solution that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

The Group has, since May 2018, traded as Yourgene Health outside of Europe (but remains as Yourgene Bioscience in Taiwan) reflecting the increased scope of the business in other areas of clinical genetics further to reproductive health; but maintains the Premaitha Health brand within Europe.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.